The role of hematopoietic stem cell transplantation (HSCT) in the treatment of serious malignant and nonmalignant hematologic disorders has rapidly expanded as a result of advances in histocompatibility typing, conditioning regimens, and supportive care. In fact, it is currently estimated that approximately 18 000 patients worldwide will receive some form of HSCT annually. 1 Even though a tremendous amount of knowledge has been amassed in transplantation biology over the years, the development of chronic graftversus-host disease (GVHD) continues to plague patients receiving HSCT and represents the major cause of late nonrelapse mortality.
Chronic GVHD has traditionally been considered to occur after day 100, 2 although recently it has been appreciated that this arbitrary time distinction is not useful given the large number of nonmyeloabative transplants and donor lymphocyte infusions, which are complicated by chronic GVHD. The clinical manifestations generally include cutaneous, hepatic, and mucosal involvement. 3 Skin is the most commonly affected tissue as 81% of cases present with cutaneous findings. These generally include lichenoid eruptions, which may progress to cutaneous sclerodermatous disease. In the sclerodermatous form of the disease, fibrosis of the skin occurs, destroying normal skin appendages.
Retroperitoneal fibrosis is a process of unknown etiology, which usually affects males between the ages of 40 and 60 years. 4 It develops gradually with nonspecific symptoms including malaise, anorexia, nausea, and vomiting. 5 The diagnosis is most commonly made using imaging studies, with CT being the exam of choice. 6 There are few effective treatment options available for patients suffering from idiopathic retroperitoneal fibrosis with most cases being managed surgically. Medical therapy is usually not effective unless the fibrosis is in response to an inflammatory condition (ie not idiopathic), in which case steroids may be effective. 7 Here, we present an unusual case of retroperitoneal fibrosis following HSCT presumably caused by chronic GVHD.
A 36-year-old female with relapsed follicular mixed lymphoma underwent allogeneic HSCT after conditioning with total body irradiation, cyclophosphamide, and Ara-C. Her immediate post transplant course was complicated by hemorrhagic cystitis requiring nephrostomy tubes/ureteral stents and biopsy proven stage 2 cutaneous GVHD, treated with low-dose steroids. After the transplant, the patient developed persistent nausea and vomiting and multiple urinary tract infections. Although the cystitis resolved, multiple attempts at removing her ureteral stents were complicated with renal insufficiency. This suggested extrinsic ureteral compression and CT scan revealed retroperitoneal fibrosis (Figure 1a ). Over time, the patient had increasing fibrosis in the pericalyceal region. Her ureters were surgically moved to the peritoneum and biopsies of the fibrotic tissue were negative for lymphoma. Although her renal function stabilized, she experienced persistent GI symptoms and a failure to thrive. She developed chylous ascites (Figure 1b) , which rapidly accumulated after large volume paracenteses. Testing for mycobacteria and histoplasma was negative. There were no liver function abnormalities and lymphoscintigraphy showed no lymphatic flow above the inguinal ligament. Laparoscopic biopsy was also negative for infectious agents. Steroids were initiated for presumed GVHD as the cause of her retroperitoneal fibrosis. Within a month, the nausea and vomiting resolved and there was no reaccumulation of ascites. After 3 months, the patient described her eating habits as 'normal', her ascites had resolved completely by CT, and her retroperitoneal fibrosis was reduced in size ( Figure 1c) . She gained 20 pounds and her ureteral stents were removed with stable renal function. At 3 years after the transplant, there was complete donor hematopoiesis and no evidence of lymphoma.
Although steroids have been used successfully in the treatment of retroperitoneal fibrosis, in these instances the fibrosis was invariably part of a broader inflammatory condition. The patient described here had no evidence of an ongoing inflammatory process. Biopsy of her retroperitoneum on two independent occasions was negative for cytology, infectious agents, or other inflammatory disease. She was unlikely to develop idiopathic retroperitoneal fibrosis given her age, gender, and previous therapy. These circumstances coupled with a dramatic and rapid response to immunosuppression support that chronic GVHD is the most likely cause of her disease.
It is interesting that chronic GVHD affects a multitude of tissues, with some such as the skin and liver being affected more commonly than others. Determining the common molecular thread between these tissues will undoubtedly play an important role in our approach to GVHD. It is also intriguing that in a few cases including the one reported here, GVHD leads to fibrosis of tissues such as the retroperitoneum without interfering with those sites that are more commonly affected. Pulmonary fibrosis has recently been described as a distinct entity separate from obliterative bronchiolitis in chronic GVHD. 8 We have also seen a patient where pulmonary fibrosis was the predominant clinical manifestation, and although the patient had transient responses to immunosuppression and terminally developed skin changes classic for sclerodermatous GVHD, he ultimately succumbed to his fibrotic lung disease. Recently, it was reported that T cells specific for a certain polymorphic segment of CD45 could induce GVHD leading only to pulmonary complications without the classical skin and liver manifestations in mice. 9 A more thorough understanding of which immune cells attack which antigens in which tissues will be instrumental for us to better predict chronic GVHD in the future and to develop drugs that are more target specific than steroids.
The observations discussed here have important implications for our understanding and management of HSCT patients who develop chronic GVHD. Perhaps, patients receiving HSCT who present with gastroparesis or other nonspecific GI symptoms without any skin or liver manifestations could have subclinical fibrosis due to undiagnosed GVHD. Although our patient responded remarkably well to steroids within a 1-month period, more specific strategies to circumvent such complications will hopefully be available as our molecular understanding of the pathogenesis of fibrosis in chronic GVHD evolves. 
